Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm

Nature Reviews Clinical Oncology, Published online: 07 July 2020; doi:10.1038/s41571-020-0399-6The availability and subsequent successes of immune-checkpoint inhibitors (ICIs) in patients with metastatic melanoma, and to a lesser extent in those with several other forms of cancer, have made long-term treatment-free remissions a realistic possibility for a subset of patients. In this Perspective, the authors describe available data on long-term remission from patients with melanoma and other solid tumours and provide early recommendations regarding the circumstances in which ICIs can be safely discontinued.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research